# Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma

> **NCT04058470** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Huiqiang Huang** · enrollment: 140 (estimated)

## Conditions studied

- Diffuse Large B Cell Lymphoma
- High-grade B-cell Lymphoma
- Follicular Lymphoma Grade IIIb
- Transformed Lymphoma
- EBV-Positive DLBCL, Nos
- ALK-Positive Anaplastic Large Cell Lymphoma

## Interventions

- **DRUG:** Toripalimab, Rituximab
- **DRUG:** R-CHOP Protocol

## Key facts

- **NCT ID:** NCT04058470
- **Lead sponsor:** Huiqiang Huang
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-04-24
- **Primary completion:** 2023-12-30
- **Final completion:** 2025-12-30
- **Target enrollment:** 140 (ESTIMATED)
- **Last updated:** 2022-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04058470

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04058470, "Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04058470. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*